R-3750 is under clinical development by Rise Therapeutics and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how R-3750’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rise Therapeutics overview
Rise Therapeutics is a biopharmaceutical company focused on developing targeted immunological-based biologics to treat immunology and inflammatory indications. Its pipeline product portfolio includes R-2487, an immunobiotic drug targeting key immunological pathway that induce specific populations of T regulatory cells to intervene with inflammatory processes; R-3750 is an immunobiotic program that induces immune homeostasis and enhancing the gut barrier for the treatment of gastrointestinal (GI) inflammatory disease. Its oral delivery platform, TriPartite X (TPX), is a novel DNA assembly approach that allows creation of recombinant probiotics to escort targeted protein therapies to the site of action, the intestinal space. Rise Therapeutics is headquartered in Rockville, Maryland, the US.
For a complete picture of R-3750’s drug-specific PTSR and LoA scores, buy the report here.